down arrow

Protalix Biotherapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74365A3095
USD
1.75
0.03 (1.74%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.691.78

52 Week

1.323.10
Valuation
Technical
Day's Volume

CASH

581.03 k

Shareholding (Mar 2025)

FII

4.11%

Held by 37 FIIs

DII

89.75%

Held by 7 DIIs

Promoter

0.00%

How big is Protalix Biotherapeutics, Inc.?

22-Jun-2025

As of Jun 18, Protalix Biotherapeutics, Inc. has a market capitalization of 109.06 million, with net sales of 59.76 million and a net profit of 3.91 million over the latest four quarters. The company reported shareholder's funds of 43.21 million and total assets of 73.42 million as of Dec 24.

Market Cap: As of Jun 18, Protalix Biotherapeutics, Inc. has a market capitalization of 109.06 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Protalix Biotherapeutics, Inc. reported net sales of 59.76 million and a net profit of 3.91 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 43.21 million and total assets of 73.42 million.

Read More

What does Protalix Biotherapeutics, Inc. do?

22-Jun-2025

Protalix Biotherapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins. As of March 2025, it reported net sales of $10 million and a net loss of $4 million, with a market cap of $109.06 million.

Overview: <BR>Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 109.06 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.74 <BR>Return on Equity: 8.64% <BR>Price to Book: 2.41<BR><BR>Contact Details: <BR>Address: 2 Snunit St., Science Park, POB 455, KARMIEL None: 2161401 <BR>Tel: 972 4 9028100 <BR>Fax: 972 4 9889489 <BR>Website: http://www.protalix.com

Read More

Who are in the management team of Protalix Biotherapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Protalix Biotherapeutics, Inc. includes Chairman Zeev Bronfeld, CEO Dror Bashan, and Directors Pol Boudes, Gwen Melincoff, Amos Bar-Shalev, David Granot, and Aharon Schwartz. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Protalix Biotherapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Zeev Bronfeld, Chairman of the Board<BR>- Mr. Dror Bashan, President, Chief Executive Officer, and Director<BR>- Dr. Pol Boudes, Director<BR>- Ms. Gwen Melincoff, Director<BR>- Mr. Amos Bar-Shalev, Independent Director<BR>- Mr. David Granot, Independent Director<BR>- Dr. Aharon Schwartz, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Protalix Biotherapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Protalix Biotherapeutics, Inc. has shifted to a mildly bullish trend, supported by positive weekly indicators and a strong 1-year return of 70.64%, despite underperforming the S&P 500 over the past 5 and 10 years.

As of 9 September 2025, the technical trend for Protalix Biotherapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by weekly MACD and KST indicators, which are both mildly bullish, along with a bullish signal from the Bollinger Bands. However, the daily moving averages remain mildly bearish, indicating some short-term weakness. The Dow Theory also confirms a mildly bullish outlook on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has shown a strong 1-year return of 70.64%, significantly outperforming the S&P 500's 17.14% over the same period. However, over the 5-year and 10-year periods, the stock has underperformed relative to the S&P 500.

Read More

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology's 4.74, despite strong operational efficiency metrics, indicating that investors should be cautious before investing.

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. with a P/E of 4.74. Additionally, Protalix's EV to EBITDA ratio stands at 15.52, while its peers are demonstrating much lower ratios, suggesting a premium valuation relative to the industry.<BR><BR>In comparison to its peers, Protalix Biotherapeutics shows a ROCE of 38.92% and a ROE of 8.64%, which are strong indicators of operational efficiency but do not justify its current valuation levels when compared to peers like Puma Biotechnology, which is classified as very attractive. The stock's recent performance against the S&P 500 is not available, but the current valuation metrics suggest that investors may want to exercise caution before investing at this price level.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 126 Million (Micro Cap)

stock-summary
P/E

32.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.64

stock-summary
Return on Equity

12.57%

stock-summary
Price to Book

2.52

Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.06%
0%
10.06%
6 Months
9.37%
0%
9.37%
1 Year
7.36%
0%
7.36%
2 Years
15.89%
0%
15.89%
3 Years
54.87%
0%
54.87%
4 Years
115.15%
0%
115.15%
5 Years
-49.71%
0%
-49.71%

Protalix Biotherapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape

Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $1.86. Over the past year, the company has outperformed the S&P 500, achieving a return of 31.91%. Key financial metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Read More
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance

Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Read More
Protalix Biotherapeutics Stock Forms Golden Cross, Signals Bullish Breakout Ahead

Protalix Biotherapeutics Stock Forms Golden Cross, Signals Bullish Breakout Ahead

Protalix Biotherapeutics, Inc. recently achieved a Golden Cross, a technical event often seen as a positive indicator. The stock outperformed the S&P 500 today and has shown remarkable growth over the past year. Various technical metrics indicate a bullish sentiment, suggesting optimism about the company's future prospects.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.84%
EBIT Growth (5y)
22.69%
EBIT to Interest (avg)
-0.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.17
Tax Ratio
24.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.98%
ROCE (avg)
58.62%
ROE (avg)
6.33%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
2.78
EV to EBIT
19.98
EV to EBITDA
15.52
EV to Capital Employed
7.78
EV to Sales
1.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
38.92%
ROE (Latest)
8.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 21 Schemes (6.14%)

Foreign Institutions

Held by 37 Foreign Institutions (4.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 55.45% vs -44.51% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 105.56% vs -155.38% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.70",
          "val2": "10.10",
          "chgp": "55.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.50",
          "val2": "-3.80",
          "chgp": "139.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.20",
          "val2": "-3.60",
          "chgp": "105.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "74.80%",
          "val2": "-409.90%",
          "chgp": "48.47%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -18.47% vs 37.61% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -65.06% vs 155.70% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "53.40",
          "val2": "65.50",
          "chgp": "-18.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.20",
          "val2": "11.70",
          "chgp": "-55.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "3.20",
          "chgp": "-65.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.90",
          "val2": "8.30",
          "chgp": "-65.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "73.40%",
          "val2": "159.70%",
          "chgp": "-8.63%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
15.70
10.10
55.45%
Operating Profit (PBDIT) excl Other Income
1.50
-3.80
139.47%
Interest
0.80
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.20
-3.60
105.56%
Operating Profit Margin (Excl OI)
74.80%
-409.90%
48.47%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 55.45% vs -44.51% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 105.56% vs -155.38% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
53.40
65.50
-18.47%
Operating Profit (PBDIT) excl Other Income
5.20
11.70
-55.56%
Interest
1.10
3.20
-65.62%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.90
8.30
-65.06%
Operating Profit Margin (Excl OI)
73.40%
159.70%
-8.63%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -18.47% vs 37.61% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -65.06% vs 155.70% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Protalix Biotherapeutics, Inc. stock-summary
stock-summary
Protalix Biotherapeutics, Inc.
Pharmaceuticals & Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
Company Coordinates stock-summary
Company Details
2 Snunit St., Science Park, POB 455 , KARMIEL None : 2161401
stock-summary
Tel: 972 4 9028100
stock-summary
http://www.protalix.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."